The bacteria corynebacterium diphtheriae produce a toxin which causes diphtheria. Diphtheria bacteria are typically transmitted from person to person through respiratory droplets such as those produced by coughing or sneezing. The bacteria produce a toxin that destroys healthy respiratory system tissues.
Global diphtheria vaccine market is estimated to be valued at US$ 5,097.9 million in 2022 and is expected to exhibit a CAGR of 5.86% during the forecast period (2022-2030).
Analysts’ Views on Global Diphtheria Vaccine Market:
The diphtheria vaccine market's growth can be driven by the increase in the research and development activities and robust pipeline for diphtheria by key market players. According to clinicaltrials.gov, China National Biotec Group Company Limited, a biotech company and Beijing Institute of Biological Products Co Ltd., a biotech company are jointly conducting clinical trials to study safety and efficacy of Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine (DTaP) in healthy infants aged 2 months and 3 months.
Figure 1.Global Diphtheria Vaccine Market Share (%), by Vaccine Types, 2022
Global Diphtheria Vaccine Market- Driver
The increase in the prevalence of diphtheria in India
The increase in the prevalence on diphtheria in India is expected to drive the market growth over the forecast period. For instance, according to data published by Knoema, a U.S. based data Technology Company, in June 2022, there were around 1,768 number of cases of diphtheria in U.S., in 2021.
The increase in the collaboration and partnership by key market players
Key market player are adopting strategies such as partnership and collaborations in order to launch new products, this is expected to drive the market growth for the forecast period. For instance, in June 2021, Sanofi, a French multinational pharmaceutical and healthcare company, announced that they have entered into a partnership with Merck & Co., Inc., an American multinational pharmaceutical company, so as to develop vaccine for Diphtheria and other disease such as Tetanus.
|Base Year:||2021||Market Size in 2022:||US$ 5,097.9 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||5.86%||2030 Value Projection:||US$ 8,037.1 Mn|
AJ Vaccines A/S., BIONET-ASIA, GlaxoSmithKline plc., MassBiologics, Meiji Holdings Co., Ltd., Merck & Co., Inc, Panacea Biotec, Sanofi, Serum Institute of India Pvt. Ltd., Bharat Biotech, and BB – NCIPD Ltd.
|Restraints & Challenges:||
Figure 2. Global Diphtheria Vaccine Market Share (%), by Region, 2022
Global Diphtheria Vaccine Market- Regional Analysis
Among regions, North America region is expected to dominate the market over the forecast period. This is attributed due to the North America hold 34.8% market share and due to presence of large number key market player in this region. Key market players such as AJ Vaccines A/S., GlaxoSmithKline plc., Merck & Co., Inc, Sanofi, and others have their strong presence in this region.
The Europe region is expected to be second largest region over the forecast period. Due to increasing prevalence of dermatological disease in Europe. For instance, in March 2022, according to article published by National Library of Medicine, in 2021, 185,103,774 individuals in Europe affected by dermatological condition or disease.
Global Diphtheria Vaccine Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.
Quarantine, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending. Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources which were required to ensure safety in hospitals and provide treatment to patients with other diseases. This has impacted the overall healthcare market negatively. Additionally, there were delays in hospitalization as number of patient visits decreased, which is expected to affect the global diphtheria vaccine market over the forecast period
Global Diphtheria Vaccine Market Segmentation:
The global diphtheria vaccine market report is segmented into vaccine types, age group, and end user
Based on Vaccine Types, the market is segmented into DTaP vaccine, DT vaccine, Tdap vaccine, and Td vaccine. Out of which, DTaP vaccine segment is expected to dominate the diphtheria vaccine market during the forecast period and this is attributed due to increase in the usage of DTaP vaccine and product launch.
Based on Age Group, the market is segmented into pediatrics, and adults. Out of which, pediatrics segment is expected to dominate the market over the forecast period and this is attributed due to increase in the research and development activities by key market players for pediatrics segment.
Based on End User, the diphtheria vaccine market is segmented into hospitals, clinics, and vaccination centers. Hospitals is expected to dominate the market over the forecast period and this is attributed to the increase in government initiatives to launch news wards for diphtheria in hospitals.
Among all segmentation, age group segment has highest potential due to high demand of diphtheria vaccine in pediatrics population. For instance, in July 2022, United Nations Children's Fund announced that 25 million children missed out on one or more doses of DTP through routine immunization services in 2021 alone.
Global Diphtheria Vaccine Market Cross Sectional Analysis:
In vaccine type segment, DTaP held as a dominant segment in Asia Pacific region due to the increasing number of research and development activities by key market players. Pediatric DTaP, a Diphtheria toxoid, tetanus toxoid, recombinant pertussis vaccine candidate is currently in phase-III of clinical trials of BIONET-ASIA, a manufacturer of vaccines.
Global Diphtheria Vaccine Market: Key Developments
According to an research article published in Frontiers Media S.A., a scientific journal, in October 2021, the study suggest that individuals with registered diphtheria or tetanus vaccinations are less likely to develop severe COVID-19 than people who had only received other vaccinations such as polio, COVID-19, and others.
On December 13, 2022, BIONET-ASIA, a vaccine manufacturing company, announced that they entered into a partnership with Pharmaniaga Berhad, a Malaysian pharmaceutical company to development of a 6-in-1 Hexavalent Vaccine. The vaccine will provide Malaysian health care providers with option to immunize children against six childhood diseases, such as diphtheria (DT), tetanus (TT), pertussis (aP), poliomyelitis (IPV), Haemophilus influenzae type b (Hib), and hepatitis B (Hep-B).
In October 2020, BIONET-ASIA, a vaccine manufacturing company announced that they have completed the Phase-II clinical trials of Tetanus, Diphtheria, Pertussis (In children, Prevention) in Thailand.
In June 2022, GSK plc, a global pharmaceutical company announced that they have invested more than US$ 1.2 Billion to accelerate research and development (R&D) dedicated to develop vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and diphtheria.
Global Diphtheria Vaccine Market: Restraint
The side effects of Diphtheria vaccine
The major factors that can hamper growth of the global diphtheria vaccine market over the forecast period include high cost of the diphtheria vaccines and inadequate access to vaccines in under developed countries. For instance, according to centers for disease control and prevention (CDC) in November 2022, the cost of Quadracel, a diphtheria vaccine manufactured by Sanofi Pasteur, a vaccines division of the French multinational pharmaceutical company Sanofi, is US$ 58.35 for a single vial. Key market player should focus on developing cost effective vaccine.
Global Diphtheria Vaccine Market: Key Players
Major players operating in the global diphtheria vaccine market include AJ Vaccines A/S., BIONET-ASIA, GlaxoSmithKline plc., MassBiologics, Meiji Holdings Co., Ltd., Merck & Co., Inc, Panacea Biotec, Sanofi, Serum Institute of India Pvt. Ltd., Bharat Biotech, and BB – NCIPD Ltd.
Diphtheria is a serious infection caused by strains of bacteria called Corynebacterium diphtheriae that make a toxin. It is the toxin that can cause people to get sick. Diphtheria bacteria spread from person to person, usually through respiratory droplets, like from coughing or sneezing. The bacteria make a toxin that kills healthy tissues in the respiratory system. Within two to three days, the dead tissue forms a thick, gray coating that can build up in the throat or nose. Vaccines are available that help prevent diphtheria, an infection caused by Corynebacterium diphtheriae bacteria. There are four kinds of Vaccines used in the U.S. to protect against diphtheria, all of which also provide protection against other diseases such as tetanus, and pertussis. The Vaccines are as follow: Diphtheria and tetanus (DT) Vaccines, Diphtheria, tetanus, and pertussis (DTaP) Vaccines, Tetanus and diphtheria (Td) Vaccines, and Tetanus, diphtheria, and pertussis (Tdap) Vaccines.
Increase in the government and non-government organizations initiatives to develop diphtheria Vaccines and increase in the awareness among people regarding importance of diphtheria Vaccine is expected to drive the market growth. Moreover, increase in the prevalence of bacterial infection such as diphtheria and tetanus is expected to drive the market growth for the forecast period. For instance, according to an article published in national library of medicine in June 2021, there were around 2,243 cases of diphtheria in Middle East during the period between 2019 to 2020. Out of which, about 44% (978/2243, 43.6%) of the cases involved children aged 5 to 15 years. Respiratory tract infection was the predominant symptom (2044/2243, 91.1%), followed by pseudomembrane (1822/2243, 81.2%).
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.